Summary Liquid biopsy is an attractive option as a supplement or alternative to tissue biopsy for applications in reproductive health, cancer and transplant medicine. Liquid biopsy involves detecting and analyzing foreign-derived biomarkers present in body fluids such as blood or urine. The origin of the biomarker defines the liquid biopsy application: tumor (cancer applications), fetus (prenatal screening applications) or transplanted organ (transplant medicine applications).
Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/3310538
Biomarker types of interest include cell-free DNA (cfDNA), circulating tumor cells (CTCs) and exosomes. Ongoing advances in sensitive molecular technologies such as next-generation DNA sequencing (NGS) and digital polymerase chain reaction (dPCR) enable detection of biomarkers that are present in fluids at very low concentrations. Competitors clusters around each of the three applications segments: non-invasive prenatal testing (NIPT), cancer and transplant medicine. Although there is recent movement across the segments by some companies.
When compared with conventional tissue biopsy, liquid biopsy tests address a significant medical need: a biopsy that is non-invasive and has little or no risk of medical complications. The validation of this testing platform and demonstration of clinical utility first occurred in the high-risk pregnancy segment of the NIPT industry, resulting in high market penetration. Substantial progress is being made in the average-risk pregnancy NIPT market segment and in some applications in cancer and transplant medicine.
Reasons for Doing This Study Conventional biopsy methods are often invasive, uncomfortable and carry risks of side effects. Liquid biopsy addresses these issues because it is non-invasive and carries little, if any, risks of side effects. In the age of genomics and personalized medicine, it is critical for clinicians to have diagnostic tools that can be used on a regular basis to screen, monitor, conduct surveillance, guide treatment or otherwise give valuable genomic information about a disease. Liquid biopsy provides this capability and is of high interest to the medical community.
Liquid biopsy-enabling technologies are coming to the forefront and provide significant market growth momentum to the industry. Downstream analysis technologies such as next-generation sequencing (NGS) and digital PCR are progressing in capabilities, efficiency and costs. Upstream technologies such as microfluidics, cell-free DNA capture and isolation, cell capture and DNA amplification are also making significant progress. Liquid biopsy is also gaining significant traction with key opinion leaders, medical societies and insurance payors.
As a result, liquid biopsy is penetrating into attractive clinical applications including average-risk, noninvasive prenatal testing and cancer therapy guidance and monitoring. Based on these trends, liquid biopsy markets are emerging rapidly and the need for industry and market characterization is great. The outstanding growth potential for liquid biopsy diagnostics makes it particularly timely for preparing this updated report.
Browse the complete report @ https://www.orbisresearch.com/reports/index/liquid-biopsy-with-emphasis-on-cancer-global-markets-to-2023
Report Scope: The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2017, 2018 and 2023 (forecasted).
This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. The report discusses several significant, large-scale research initiatives that are contributing to liquid biopsy development. Key forces driving the market are enumerated.
The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2017 through November 2018. Industry subsectors analyzed include advanced sequencing instruments, droplet digital PCR (polymerase chain reaction), target enrichment, single-cell DNA polymerase, non-invasive prenatal testing (NIPT), fetal-cell NIPT, CTC (circulating tumor cell) capture and detection and liquid biopsy.
The market for liquid biopsy diagnostics is analyzed in depth. The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics and other), analysis purpose (screening/ early detection, diagnosis, therapy guidance, monitoring) and geography (North America, Europe, Asia Pacific, Rest of the World). Market data covers 2017, 2018 and 2023 (forecasted). More than 175 companies in the liquid biopsy industry are profiled in this report. BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2017 through November 2018, including key alliance trends.
- 27 data tables and 70 additional tables
- An overview of the global markets for liquid biopsy technologies, applications, industry subsegments
- Analyses of global market trends with data from 2017 to 2018 and projections of compound annual growth rates (CAGRs) through 2023
- Regional dynamics of the liquid biopsy diagnostics market covering North America, Europe, APAC and rest of the world covering other emerging economies
- Discussion of major drivers, current trends and global outlook of liquid biopsy technologies, their growth potential and factors that influence the market
- Examination of various conventional biopsy methods and highlight how liquid biopsy enabling technologies address the issues and are gaining significant traction with key opinion leaders
- Comparative study of liquid biopsy with conventional biopsy technologies and coverage of their respective biomarkers
- Comprehensive company profiles of key market players within the industry, including Apocell Inc., Becton, Dickinson and Co., Clinical Genomics Technologies, Exact Sciences Corp. and Thermo Fisher Scientific Inc.
Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/3310538
Companies Mentioned: ACCURAGEN INC. ADAPTIVE BIOTECHNOLOGIES INC. ADVANCED CELL DIAGNOSTICS INC. AGILENT TECHNOLOGIES, INC. AKADEUM LIFE SCIENCES ALCEDIAG AMOY DIAGNOSTICS CO. LTD. ANGLE PLC APOCELL INC. APOSTLE INC. ARCEDI BIOTECH APS ARUP LABORATORIES ASURAGEN INC. ATRECA INC. AVIVA BIOSCIENCES BAYLOR GENETICS BECTON, DICKINSON AND CO. BELLWETHER BIO INC. BERRY GENOMICS CO. LTD. BGI SHENZHEN BIO-RAD LABORATORIES INC. BIO-TECHNE LTD. BIOCARTIS NV BIOCEPT INC. BIOCORE CO. LTD. BIODESIX INC. BIOFLUIDICA INC. BIOGAZELLE BIOMARX INC. BIOVENDOR-LABORATORNI MEDICINA A.S. BLUESTAR GENOMICS INC. BOREAL GENOMICS CANCER GENETICS INC. CAREDX INC. CEGAT GMBH CELL MICROSYSTEMS INC. CELLMAX LIFE CELSEE DIAGNOSTICS CHRONIX BIOMEDICAL CIRCULOGENE THERANOSTICS CIRCULOMICS INC. CLINICAL GENOMICS TECHNOLOGIES CODIAK BIOSCIENCES COLOR GENOMICS CS GENETICS LTD. CYGNUS BIOSCIENCES CO. LTD. CYNVENIO BIOSYSTEMS INC. CYTOTRACK APS DATAR CANCER GENETICS LTD. DIACARTA INC. DIAGNOLOGIX LLC DIAGNOMICS DIRECT GENOMICS CO. LTD. DNA ELECTRONICS LTD. DNALYTICS DNANEXUS INC. DOVETAIL GENOMICS LLC ENVISION GENOMICS EPIC SCIENCES INC. EUROFINS SCIENTIFIC EXACT SCIENCES CORP. EXOSOME SCIENCES INC. EXPEDEON AG EZLIFE BIO INC. FABRIC GENOMICS FLUXION BIOSCIENCES INC. FREENOME INC. GENAPSYS INC. GENEDX INC. GENESEQ BIOSCIENCES PTY LTD. GENETICS RESEARCH LLC GENEXOSOME TECHNOLOGIES INC. GENOMATIX GMBH GENOMIC HEALTH INC. GENOMONCOLOGY GENOSPACE GIGAGEN INC. GOLDEN HELIX GRAIL INC. GUARDANT HEALTH INC. HELITEC HELIX OPCO LLC HTG MOLECULAR DIAGNOSTICS INC. ILLUMINA INC. IMMUNOVIA AB INEX INNOVATIONS EXCHANGE PTE. LTD. INIVATA LTD. INTERPACE DIAGNOSTICS LLC INVITAE INC. INVIVOSCRIBE INC. JBS SCIENCE INC. KONINKLIJKE PHILIPS N.V. LABORATORY CORP. OF AMERICA INC. LEXENT BIO INC. LUCENCE DIAGNOSTICS PTE. LTD. MAMMOTH BIOSCIENCES INC. MDNA LIFE SCIENCES INC. MDXHEALTH INC. MEDGENOME LABS PVT. LTD. MEDOMICS LLC MENARINI SILICON BIOSYSTEMS SPA MERCK KGAA MOLECULAR HEALTH GMBH MYRIAD GENETICS INC. N-OF-ONE INC. NAMOCELL INC. NANOSTRING TECHNOLOGIES INC. NANOVIEW BIOSCIENCES INC. NATERA INC. NAVERIS INC. NEOGENOMICS LABORATORIES NEW ENGLAND BIOLABS NEW ONCOLOGY GMBH NIPD GENETICS NOVOGENE CO. LTD. NUGEN TECHNOLOGIES INC. NUPROBE INC. NX PRENATAL INC. ONCOCYTE CORP. ONCODNA S.A. OXFORD NANOPORE TECHNOLOGIES LTD. PACIFIC BIOSCIENCES OF CALIFORNIA INC. PANGAEA ONCOLOGY PARADIGM DIAGNOSTICS INC. PARSEQ LAB CO. LTD. PATHWAY GENOMICS CORP. PERSONAL GENOME DIAGNOSTICS INC. PIERIANDX PORTABLE GENOMICS LLC PRECIPIO INC. PREDICINE INC. PREMAITHA HEALTH PLC PRENETICS PROVISTA DIAGNOSTICS INC. QIAGEN NV QUANTAPORE INC. QUANTUM BIOSYSTEMS INC. QUANTUMDX QUEST DIAGNOSTICS INC. RARECELLS SAS RARECYTE INC. REAL TIME GENOMICS INC. RESOLUTION BIOSCIENCE INC. ROCHE HOLDING AG SCREENCELL SEEKIN SENGENICS LTD. SEQUENCING.COM SEVEN BRIDGES GENOMICS INC. SINGLERA GENOMICS INC. SOPHIA GENETICS SPERA MEDICAL SPHERE FLUIDICS LTD. STILLA TECHNOLOGIES STRAND LIFE SCIENCES PVT. LTD. STRATOS GENOMICS INC. SYAPSE SYSMEX INOSTICS GMBH TAI DIAGNOSTICS INC. TAKARA BIO INC. THERMO FISHER SCIENTIFIC INC. THORNE DIAGNOSTICS INC. TRANSPLANT GENOMICS TROVAGENE INC. TWINSTRAND BIOSCIENCES TWO PORE GUYS INC. TYMORA ANALYTICAL OPERATIONS LLC UBIQUITY GENOMICS INC. VELA DIAGNOSTICS VOLITIONRX VORTEX BIOSCIENCES XING TECHNOLOGIES LLC YIKON GENOMICS CO. LTD.
About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Us: Hector Costello Senior Manager – Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A. Phone No.: +1 (214) 884-6817; +91 895 659 5155